Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
์ข
๋ชฉ ์ฝ๋ STTK
ํ์ฌ ์ด๋ฆShattuck Labs Inc
์์ฅ์ผOct 09, 2020
CEOSchreiber (Taylor)
์ง์ ์44
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃOct 09
์ฃผ์500 W. 5Th Street
๋์AUSTIN
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ78701
์ ํ15129004690
์น์ฌ์ดํธhttps://www.shattucklabs.com/
์ข
๋ชฉ ์ฝ๋ STTK
์์ฅ์ผOct 09, 2020
CEOSchreiber (Taylor)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์